Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Lifts TPs for HANSOH PHARMA, CMS on Expectations of Continued Growth for Pharmas
Recommend 24 Positive 40 Negative 13 |
||||
|
||||
|
Three Chinese pharma companies, SINO BIOPHARM (01177.HK), HANSOH PHARMA (03692.HK), and CMS (00867.HK), recorded solid results for 1H25 and achieved double-digit revenue growth in both 2H25 and 1H25, according to a research report by CLSA. In the broker's estimate, their momentum will persist into 2H25 on tailwinds such as the launch of more innovative drugs, increased sales of new products, a more favorable environment for Chinese healthcare insurance spending, and potential business development (BD) revenue. CLSA reiterated an Outperform rating for SINO BIOPHARM with a target price kept at HKD9.2. Both HANSOH PHARMA's and CMS' ratings were also reiterated as Outperform, with target prices lifted from HKD27.8 to HKD43.1 for the former and from HKD10 to HKD15.6 for the latter. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
